In the trial that led to the approval, apalutamide (Erleada) delayed cancer metastasis for men with prostate cancer that is resistant to androgen deprivation therapy.
from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader http://ift.tt/2IcNkBl
In the trial that led to the approval, apalutamide (Erleada) delayed cancer metastasis for men with prostate cancer that is resistant to androgen deprivation therapy.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου